These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 445500)
41. Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. Kvols LK; Eagan RT; Myers RP Cancer Treat Rep; 1977; 61(2):311-2. PubMed ID: 326400 [No Abstract] [Full Text] [Related]
42. Melphalan in metastatic cancer of the prostate. Franks CR Cancer Treat Rev; 1979 Jun; 6 Suppl():121-5. PubMed ID: 498165 [No Abstract] [Full Text] [Related]
43. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial. Moore MR; Troner MB; DeSimone P; Birch R; Irwin L Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053 [No Abstract] [Full Text] [Related]
44. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer. Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265 [No Abstract] [Full Text] [Related]
45. Melphalan in metastatic cancer of the prostate: a pilot study. Franks CR Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500 [No Abstract] [Full Text] [Related]
46. Acid phosphatase, alkaline phosphatase and prostate-specific antigen--usefulness in the diagnosis of metastatic disease and follow-up. Bauer HW Prog Clin Biol Res; 1988; 269():33-42. PubMed ID: 2455908 [TBL] [Abstract][Full Text] [Related]